Source: Hematology. Unidade: FM
Subjects: LEUCEMIA, HEMATOPOESE, RECIDIVA LOCAL DE NEOPLASIA, IMUNOTERAPIA, ANTICORPOS MONOCLONAIS, ANTINEOPLÁSICOS, RESULTADO DE TRATAMENTO
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
SILVA, Wellington Fernandes da et al. Primary refractory B-cell lymphoblastic leukemia with extramedullary disease - a distinctive response to blinatumomab and inotuzumab ozogamicin. Hematology, v. 41, n. 4, p. 356-359, 2019Tradução . . Disponível em: https://doi.org/10.1016/j.htct.2018.11.004. Acesso em: 21 maio 2024.APA
Silva, W. F. da, Marquez, G. L., Salim, R. C., & Rocha, V. G. (2019). Primary refractory B-cell lymphoblastic leukemia with extramedullary disease - a distinctive response to blinatumomab and inotuzumab ozogamicin. Hematology, 41( 4), 356-359. doi:10.1016/j.htct.2018.11.004NLM
Silva WF da, Marquez GL, Salim RC, Rocha VG. Primary refractory B-cell lymphoblastic leukemia with extramedullary disease - a distinctive response to blinatumomab and inotuzumab ozogamicin [Internet]. Hematology. 2019 ; 41( 4): 356-359.[citado 2024 maio 21 ] Available from: https://doi.org/10.1016/j.htct.2018.11.004Vancouver
Silva WF da, Marquez GL, Salim RC, Rocha VG. Primary refractory B-cell lymphoblastic leukemia with extramedullary disease - a distinctive response to blinatumomab and inotuzumab ozogamicin [Internet]. Hematology. 2019 ; 41( 4): 356-359.[citado 2024 maio 21 ] Available from: https://doi.org/10.1016/j.htct.2018.11.004